Skip to Content
Search Menu

SABCS2020: Robust survival outcome in HER2 positive metastatic breast cancer

Hear Shanu Modi, Memorial Sloan Kettering Cancer Center, New York, presents the updated results of treatment with trastuzumab deruxtecan in patients with HER2 positive metastatic breast cancer.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Related

P-VERIFY: Kattava tosielämän kokonaiselossaolon (OS) vertaileva analyysi CDK4/6-estäjistä yhdessä aromataasi-inhibiittorin kanssa HR+/HER2- metastasoituneessa rintasyövässä

/ Pfizer
Breast cancer
Per Hall

Making Primary Breast Cancer Prevention a Reality

/ Per Hall
Breast cancer Play the Video 03:48
Philip Poortmans

Breast Cancer Treatment: The Role of Boost Radiation Therapy in Reducing Recurrence Risks

/ Philip Poortmans
Breast cancerOnkologisk Forum 2024 Play the Video 06:45
Demet Özcan

Breast Cancer: The Prognostic Value of Tumor-Infiltrating Lymphocytes

/ Demet Özcan
Breast cancerSABCS24 Play the Video 06:43
Hope Rugo

Abemaciclib Shows Significant Benefit for HR-Positive HER2-Negative Patients with Advanced Breast Cancer

/ Hope S. Rugo
Breast cancer Play the Video 11:57
Maren Marie Andreassen

MRI-Based AI Can Detect Responsive Treatment of Breast Cancer After Three Weeks of Therapy

/ Maren Marie Andreassen
Breast cancerNBCN Play the Video 02:20
Adam Brufsky

SABCS 2024: Palbociclib, Abemaciclib, and Ribociclib Can Be Considered Equivalent in the Treatment of HR-Positive/HER2-Negative Metastatic Breast Cancer

/ Adam Brufsky
Breast cancerSABCS24 Play the Video 08:56
Stefania Katrin Finnsdottir

The Need to Improve Compliance with Adjuvant Endocrine Therapy in Hormone Receptor-Positive Breast Cancer

/ Stefanía Katrín Finnsdóttir
Breast cancerNBCN Play the Video 02:45
Minna Tanner

The Approval of New Drugs Should Be Harmonized Across the Nordic Countries

/ Minna Tanner
Breast cancerNBCN Play the Video 03:20
Back to top